Parkinson's Disease Treatment Market Trending in Pharma Industry

“Parkinson’s disease treatment market projected to grow at a CAGR of 6.1%”

The Parkinson’s disease treatment market is expected to grow from USD 4.24 billion in 2017 to USD 5,694.1 million in 2022 to grow at a CAGR of 6.1%. Factors such as the increasing aging population worldwide and government funding for research on Parkinson’s disease are driving this market. However, the availability of alternative treatments is expected to restrain this market.

“The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period”

On the basis of drug class, the Parkinson’s disease treatment market is classified into carbidopa/levodopa, dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest growth rate during the forecast period. The growth of this market segment is mainly driven by its potency and wide adoption in the treatment of Parkinson’s disease.

“The online pharmacies segment to grow at the fastest rate during the forecast period”

By distribution channel type, the Parkinson’s disease treatment market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register highest CAGR during the forecast period. Advantages such as 24/7 ordering, home delivery, and discounts on medicines are the driving factors for this segment.

“Europe to hold the largest share of the regional market during the forecast period”

Geographically, the Parkinson’s disease treatment market is dominated by Europe, followed by North America, Asia, and the Rest of the World (RoW). Europe is expected to command the largest share of the Parkinson’s disease treatment market. The large share of this segment can be attributed to the growing aging population, presence of key players, and increasing healthcare expenditure in the region. The Asian region is estimated to grow at the fastest rate during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

·         By Company Type - Tier 1 – 70% and Tier 2 – 30%

·         By Designation – C-level – 62%, Director Level – 21%, Others – 17%

·         By Region – North America – 50%, Europe – 20%, Asia – 30%

To Know More @https://www.marketsandmarkets.com/Market-Reports/parkinson-disease-treatment-market-47265247.html